康华生物
(300841)
| 流通市值：66.72亿 | | | 总市值：71.31亿 |
| 流通股本：1.22亿 | | | 总股本：1.30亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 538,353,610.55 | 172,451,817.58 | 1,165,000,864.15 | 840,062,581.82 |
| 营业收入 | 538,353,610.55 | 172,451,817.58 | 1,165,000,864.15 | 840,062,581.82 |
| 二、营业总成本 | 373,656,732.19 | 140,114,140.64 | 895,140,732.6 | 613,116,128.08 |
| 营业成本 | 55,101,151.48 | 15,556,376.7 | 92,797,651.6 | 64,779,534.41 |
| 税金及附加 | 8,201,158.17 | 4,423,443.75 | 10,257,759.34 | 6,102,420.62 |
| 销售费用 | 215,581,747.95 | 74,350,518.57 | 557,553,219.81 | 379,851,048.58 |
| 管理费用 | 55,832,163.01 | 26,137,056.88 | 120,645,222.39 | 82,608,370.51 |
| 研发费用 | 40,495,186.45 | 20,447,722.13 | 118,389,362.42 | 83,001,056.64 |
| 财务费用 | -1,554,674.87 | -800,977.39 | -4,502,482.96 | -3,226,302.68 |
| 其中:利息费用 | 342,424.57 | 349,076.96 | 3,681,028.2 | 2,858,721.58 |
| 其中:利息收入 | 1,937,307.63 | 1,175,245.04 | 8,149,793.62 | 6,038,610.81 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 4,558,765.9 | 1,901,607 | -3,572,949.83 | 1,897,619.2 |
| 加:投资收益 | 2,518,787.98 | 51,888.92 | 5,433,347.58 | 3,010,488.97 |
| 资产处置收益 | - | - | -8,912.45 | -8,912.45 |
| 资产减值损失(新) | -6,309,973.61 | -3,983,038.6 | -8,089,709.48 | -7,687,974.43 |
| 信用减值损失(新) | -8,881,452.36 | -1,786,610.35 | -11,509,086.35 | -4,320,450.39 |
| 其他收益 | 2,434,140.38 | 1,157,320.52 | 7,757,519.9 | 1,863,267.02 |
| 四、营业利润 | 159,017,146.65 | 29,678,844.43 | 259,870,340.92 | 221,700,491.66 |
| 加:营业外收入 | 6,000 | 6,000 | - | - |
| 减:营业外支出 | 142,570.19 | 141,830.79 | 127,132.87 | 46,493.28 |
| 五、利润总额 | 158,880,576.46 | 29,543,013.64 | 259,743,208.05 | 221,653,998.38 |
| 减:所得税费用 | 17,731,276.07 | 2,179,596.17 | 39,845,273.01 | 32,543,277.62 |
| 六、净利润 | 141,149,300.39 | 27,363,417.47 | 219,897,935.04 | 189,110,720.76 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 141,149,300.39 | 27,363,417.47 | 219,897,935.04 | 189,110,720.76 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 141,149,300.39 | 27,363,417.47 | 219,897,935.04 | 189,110,720.76 |
| 扣除非经常损益后的净利润 | 134,181,507.15 | 25,259,074.33 | 211,907,992.18 | 183,318,264.19 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.09 | 0.21 | 1.69 | 1.46 |
| (二)稀释每股收益 | 1.09 | 0.21 | 1.69 | 1.46 |
| 九、综合收益总额 | 141,149,300.39 | 27,363,417.47 | 219,897,935.04 | 189,110,720.76 |
| 归属于母公司股东的综合收益总额 | 141,149,300.39 | 27,363,417.47 | 219,897,935.04 | 189,110,720.76 |
| 公告日期 | 2026-08-18 | 2026-04-21 | 2026-04-21 | 2025-10-17 |
| 审计意见(境内) | | | 标准无保留意见 | |